Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Shaodong Hong"'
Autor:
Tao Chen, Li-na He, Chen Chen, Yixin Zhou, Zuan Lin, Haifeng Li, Shaodong Hong, Xuanye Zhang, Li Zhang, Yuhong Wang
Publikováno v:
Cancer Immunology, Immunotherapy. 71:1247-1255
The use of anti-programmed cell death-1 (PD-1) antibodies in treating malignancies is increasing; however, most registered clinical trials on anti-PD-1 antibodies exclude patients infected with hepatitis B virus (HBV). This retrospective study aimed
Autor:
Yixin Zhou, Chen Chen, Xuanye Zhang, Hongyun Zhao, Zuan Lin, Wenfeng Fang, Yan Huang, Wei Du, Tao Chen, Shaodong Hong, Li-na He, Yunpeng Yang, Sha Fu, Qiaozhen Hu, Li Zhang, Haifeng Li, Yongluo Jiang
Publikováno v:
Lung Cancer. 158:1-8
Systemic inflammation plays an important role in carcinogenesis and is associated with overall survival in patients with different cancer types, including those treated with immune checkpoint blockade (ICB). Serum Amyloid A (SAA) is an acute-phase pr
Autor:
Chen Chen, Bei Zhang, Yixin Zhou, Hui Yu, Shaodong Hong, Xuanye Zhang, Ping Chen, Xiuyu Cai, Li-na He
Publikováno v:
Cancer Immunology, Immunotherapy. 71:637-644
Programmed cell death-ligand 1 inhibitors plus chemotherapy (PD-L1 + Chemo) have achieved substantial progress in extensive-stage small-cell lung cancer (ES-SCLC). However, evidence about programmed cell death 1 inhibitors plus chemotherapy (PD-1 + C
Autor:
Zuan Lin, Teresa Moran, Shaodong Hong, Dan Tian, Yixin Zhou, Tao Chen, Li-na He, Sha Fu, Yuhong Wang, Xuanye Zhang, Ross A. Soo, In-Jae Oh, Haifeng Li, Satoshi Watanabe, Li Zhang, Francesco Passiglia, Ernest Nadal, Yue Chen, Chen Chen, Alessandro Russo
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Transl Lung Cancer Res
Translational Lung Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Universidad de Barcelona
Transl Lung Cancer Res
Translational Lung Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background: The aim of this study was to evaluate the safety and survival outcomes of anti-programmed cell death (PD)-1/programmed cell death-ligand 1 (PD-L1) monotherapy in patients with advanced nonsmall cell lung cancer (NSCLC) and different hepat
Autor:
Hongyun Zhao, Longyun Chen, Yunpeng Yang, Liao Yuwei, Gao Zhibo, Yan Huang, Yaxiong Zhang, Li Zhang, Shaodong Hong, Su Xiaofan, Jin Haoxuan, Yuxiang Ma, Wenfeng Fang, Shengqiang Xu, Huaqiang Zhou, Yuming He
Publikováno v:
Molecular Cancer, Vol 20, Iss 1, Pp 1-6 (2021)
Molecular Cancer
Molecular Cancer
Autor:
Wenfeng Fang, Ting Zhou, Hongyun Zhao, Li Zhang, Yunpeng Yang, Jiayi Shen, Wei Xian, Jiaqing Liu, Shaodong Hong, Yan Huang, Yaxiong Zhang, Yuxiang Ma, Zhonghan Zhang, Huaqiang Zhou
Publikováno v:
MedComm
Comprehensive studies in second primary cancer (SPC) after the initial primary human papillomavirus (HPV)‐related cancer still remain warranted. We aimed to analyze the incidence and risk factors of SPC after HPV‐related cancer. We identified 86
Autor:
Wenfeng Fang, Ting Zhou, Yaxiong Zhang, Yunpeng Yang, Jiaqing Liu, Huaqiang Zhou, Yan Huang, Jiayi Shen, Wei Xian, Hongyun Zhao, Shaodong Hong, Li Zhang, Zhonghan Zhang
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:177-181
Previous researches have indicated physical activity (PA) may be associated with lower risk of lung cancer. However, causal relationship between PA and risk of lung cancer is not clear. We aimed to inspect the causal effect of PA on lung cancer. We a
Autor:
Xue Wu, Wenfeng Fang, Hongyun Zhao, Yunpeng Yang, Yan Huang, Yuxiang Ma, Hua Bao, Shaodong Hong, Ao Wang, Li Zhang, Yang W. Shao, Fufeng Wang, Jiani C. Yin, Huaqiang Zhou
Publikováno v:
Clinical and Translational Medicine, Vol 10, Iss 1, Pp 331-336 (2020)
Clinical and Translational Medicine
Clinical and Translational Medicine
Autor:
Bei Zhang, Yixin Zhou, Shaodong Hong, Yanyu Cai, Yaqiong Zhang, Hui Yu, Li Zhang, Guifang Guo, Xiuyu Cai
Publikováno v:
Clinical and Translational Medicine, Vol 10, Iss 1, Pp 107-115 (2020)
Clinical and Translational Medicine
Clinical and Translational Medicine
Background Nivolumab plus ipilimumab (N‐I) or pembrolizumab (PEM) is associated with survival improvement as chemotherapy‐free, first‐line treatment for patients with advanced non‐small cell lung carcinoma (NSCLC) and positive programmed cell
Autor:
Qiufan Zheng, Yaxiong Zhang, Wenfeng Fang, Ting Zhou, Li Zhang, Yuxiang Ma, Xue Hou, Yunpeng Yang, Yuanyuan Zhao, Yan Huang, Hongyun Zhao, Shaodong Hong
Publikováno v:
Clinical and Translational Medicine, Vol 9, Iss 1, Pp 1-10 (2020)
Clinical and Translational Medicine
Clinical and Translational Medicine
Background Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30–40% of patients still show limited response. There is therefore a need to